SB257049
Vaccineexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2017 (NCT03276962)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04661579 | Phase 2 | Nov 6, 2020 | Bill and Melinda Gates Foundation, DF/Net Research, GlaxoSmithKline, Kenya Medical Research Institute, Kombewa Clinical Research Center, PATH, Triclinium Clinical Trial Project Management, United States Army |
| NCT03824236 | Phase 2 | Feb 5, 2019 | GlaxoSmithKline, PATH |
| NCT03276962 | Phase 2 | Sep 28, 2017 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 2 | 1 | 2017 |
| PATH | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| DF/Net Research | For profit | 1 | 0 | 1 | 2020 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Kombewa Clinical Research Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Triclinium Clinical Trial Project Management | For profit | 1 | 0 | 1 | 2020 |
| United States Army | Government | 1 | 0 | 1 | 2020 |
8 organizations
Page 1 / 1